StockData
Castle Biosciences Inc logo

Castle Biosciences Inc (CSTL) stock

CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/304% below fair value
$33.38+0.40 (+1.21%)

Close on Nov 18, 2026Market cap $1.02BP/E –Yield 0.00%

Castle Biosciences operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Castle Biosciences's operating income for the twelve months ending Sep 30, 2026 was -$28.04M. For fiscal 2025 it was -$42.81M, down 593.8% from the year before. The highest annual figure on record is $8.67M in fiscal 2024.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$42.81M-593.8%
FY2024Dec 31, 2024$8.67M–
FY2023Dec 31, 2023-$67.98M–
FY2022Dec 31, 2022-$72.86M–
FY2021Dec 31, 2021-$40.08M–
FY2020Dec 31, 2020-$6.54M-189.3%
FY2019Dec 31, 2019$7.33M–
FY2018Dec 31, 2018-$3.84M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$2.73M–
Q2 FY2026Jun 30, 2026-$3.07M–
Q1 FY2026Mar 31, 2026-$18.41M–
Q4 FY2025Dec 31, 2025-$3.83M-194.5%
Q3 FY2025Sep 30, 2025-$6.80M-234.0%
Q2 FY2025Jun 30, 2025-$4.25M-184.8%
Q1 FY2025Mar 31, 2025-$27.93M–
Q4 FY2024Dec 31, 2024$4.05M–
Q3 FY2024Sep 30, 2024$5.08M–
Q2 FY2024Jun 30, 2024$5.01M–
Q1 FY2024Mar 31, 2024-$5.47M–
Q4 FY2023Dec 31, 2023-$5.66M–
Q3 FY2023Sep 30, 2023-$9.64M–
Q2 FY2023Jun 30, 2023-$21.16M–
Q1 FY2023Mar 31, 2023-$31.52M–
Q4 FY2022Dec 31, 2022-$22.83M–
Q3 FY2022Sep 30, 2022-$21.54M–
Q2 FY2022Jun 30, 2022-$3.97M–
Q1 FY2022Mar 31, 2022-$24.52M–
Q4 FY2021Dec 31, 2021-$15.17M–
Q3 FY2021Sep 30, 2021-$11.81M–
Q2 FY2021Jun 30, 2021-$8.81M–
Q1 FY2021Mar 31, 2021-$4.28M-513.5%
Q4 FY2020Dec 31, 2020-$3.03M-216.0%
Q3 FY2020Sep 30, 2020-$3.90M-188.1%
Q2 FY2020Jun 30, 2020-$645.00K-206.1%
Q1 FY2020Mar 31, 2020$1.04M–
Q4 FY2019Dec 31, 2019$2.61M-45.2%
Q3 FY2019Sep 30, 2019$4.43M–
Q2 FY2019Jun 30, 2019$608.00K–
Q1 FY2019Mar 31, 2019-$322.00K–
Q4 FY2018Dec 31, 2018$4.77M–
Q3 FY2018Sep 30, 2018-$2.85M–
Q2 FY2018Jun 30, 2018-$2.67M–

More Castle Biosciences figures

See a number that looks wrong?